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ABSTRACT
ATM and ATR protein kinases play a crucial role
in cellular DNA damage responses. The inhibition
of ATM and ATR can lead to the abolition of the
function of cell cycle checkpoints. In this regard,
it is expected that checkpoint inhibitors can serve
as sensitizing agents for anti-cancer chemo/radio-
therapy. Although several ATM inhibitors have been
reported, there are no ATR-specific inhibitors cur-
rently available. Here, we report the inhibitory effect
of schisandrin B (SchB), an active ingredient of
Fructus schisandrae, on ATR activity in DNA
damage response. SchB treatment significantly
decreased the viability of A549 adenocarcinoma
cells after UV exposure. Importantly, SchB treat-
ment inhibited both the phosphorylation levels of
ATM and ATR substrates, as well as the activity of
the G2/M checkpoint in UV-exposed cells. The pro-
tein kinase activity of immunoaffinity-purified ATR
was dose-dependently decreased by SchB in vitro
(IC50: 7.25mM), but the inhibitory effect was not
observed in ATM, Chk1, PI3K, DNA-PK, and mTOR.
The extent of UV-induced phosphorylation of p53
and Chk1 was markedly reduced by SchB in ATM-
deficient but not siATR-treated cells. Taken
together, our demonstration of the ability of SchB
to inhibit ATR protein kinase activity following
DNA damage in cells has clinical implications in
anti-cancer therapy.
INTRODUCTION
Ultraviolet (UV), ionizing radiation (IR) as well as many
anti-cancer drugs induce DNA damage and activate cellu-
lar responses, such as DNA damage checkpoint signaling
cascades, resulting in cell cycle arrest at the G1/S, intra-S
and G2/M phases. This allows time for damage repair, or
leads to apoptosis when the extent of DNA damage is not
compatible with cell survival (1,2). Thus, DNA damage
checkpoints, which prevent the passage of damaged
DNA to the next generation of cells, can hamper tumor
progression by inducing tumor cell death in patients
undergoing chemo/radiotherapies (3).
ATM [ataxia telangiectasia (AT) mutated] and ATR
(ataxia telangiectasia and Rad-3-related) protein kinases
act as master controllers in DNA damage checkpoint sig-
naling (1,2,4,5). ATM-deﬁcient AT cells, which are
derived from human AT patients, were found to exhibit
chromosomal instability, telomere shortening and defects
in cellular responses to DNA double-strand breaks
(DSBs) following exposure to IR and radiomimetic che-
micals (1). On the other hand, in vivo functions of ATR
are less understood than those of ATM because animals
with homozygous ATR gene disruption, unlike ATM, are
embryonic lethal (6,7). However, cellular functions of
ATR have recently been investigated using small interfer-
ing RNA (siRNA) and the over-expression of kinase-deﬁ-
cient mutants in cultured cells (7–9). The transient
knockdown of ATR by siRNA was found to cause prom-
inent chromosome instability and mitotic catastrophe in
cells (10,11).
Given that most cancer cells do not have functional p53
(12,13), a key molecule for G1/S checkpoint control, the
use of inhibitors of the G2/M checkpoint can selectively
sensitize p53-defective cancer cells to the cytotoxic eﬀect
of DNA-damaging anti-cancer drugs (14,15). Thus, the
G2/M checkpoint may serve as a drug target, which is
more useful than the G1/S checkpoint in anti-cancer ther-
apy. The discovery of speciﬁc inhibitors of ATM and
ATR is beneﬁcial both for our understanding of the fun-
damental functions of these kinases and for potential
clinical applications through checkpoint abrogation in
anti-cancer therapy. Although several ATM/ATR inhibi-
tors have been reported (14), a speciﬁc compound that
inhibits ATR protein kinase has yet to be discovered.
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a number of herbal extracts and ingredients. Among
them, schisandrin B (SchB) was the most active. SchB is
a dibenzocyclooctadiene derivative isolated from Fructus
Schisandrae, the fruit of Schisandra chinensis, which is
commonly used in traditional Chinese medicine for the
treatment of hepatitis and myocardial disorders (16,17).
A recent study reported that SchB treatment enhances
the eﬀect of doxorubicin (DOX), a topoisomerase II inhi-
bitor, which induces cell death via caspase-9 activation in
SMMC7721 (human liver carcinoma) and MCF-7 (human
breast adenocarcinoma) cells (18). Presumably, SchB aug-
ments the DOX-induced apoptotic pathway upstream of
caspase-9. Alternatively, it is possible that SchB might
produce an inhibitory eﬀect on ATM and/or ATR,
which are activated after DNA damage induced by
DOX in cancer cells (19,20).
Here, we demonstrate that SchB speciﬁcally inhibits
ATR kinase activity in vitro, and that treating cells with
SchB reduces the extent of in vivo phosphorylation of
ATR substrates as well as the abrogation of G2/M check-
points following UV (but not IR) irradiation. Consistent
with the inhibition of ATR by SchB, our studies with
siRNA and AT cells show that the cytotoxic eﬀect of
SchB on cancer cells is dependent on the presence of
ATR but not ATM kinase.
MATERIALS AND METHODS
Cell culture
Human adenocarcinoma A549 cells (ATCC: American
Tissue Type Collection, VA, USA) and GM18366 Seckel
syndrome cells (Coriell Cell Repositories, NJ, USA) were
maintained in Dulbecco’s modiﬁed eagle medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS) and antibiotics (100mg/ml streptomycin and
100units/ml penicillin), all were purchased from
Invitrogen (CA, USA). AT2KY cells were obtained
from Health Science Research Resources Bank (Osaka,
Japan), and cultured in RPMI-1640 medium containing
15% FBS and antibiotics. DNA damage of cells was
induced by UV irradiation (Stratagene, Stratalinker
model 2400, CA, USA) or gIR irradiation (
137Cs, 2Gy/
min, PS-3000SB, Pony Industry Co., Osaka, Japan).
Chemicals and reagents
SchB was isolated from the petroleum extract of Fructus
schisandrae, and had greater than 95% purity, as assessed
by HPLC and described by Ip et al. (20). The drug was
dissolved in dimethyl sulfoxide (DMSO) at 10mg/ml. For
cell treatments, the drug solution was further diluted
in culture medium with a ﬁnal DMSO concentration
<5mg/ml. The proteasome inhibitor (N-acetyl-L-Leucyl-
L-Leucyl-L-norleucinal: LLnL) for the immunoblot assay
of p53 was purchased from Sigma (MO, USA). MEKs
inhibitor (PD098059) and PMA were obtained from
Sigma and Tocris (MO, USA), respectively. Caﬀeine was
purchased from Sigma.
Protein preparation
Cells were harvested by scraping into ice-cold phosphate-
buﬀered saline (PBS), and proteins were extracted from
cell pellets into UTB buﬀer (8mM urea, 150mM
2-mercaptoethanol, 50mM Tris, pH 7.5) for immunoblot
analysis, or IP buﬀer [10mM Tris, 1mM EDTA, 1mM
EGTA, 150mM NaCl, 0.5% NP-40, 1% Triton X-100,
1mM phenylmethanesulfonyl ﬂuoride (PMSF), 2mg/ml
pepstatin, 2mg/ml aprotinin and dithiothreitol (DDT),
pH 7.4] for the ATR kinase assay. Protein concentrations
were determined using a protein assay kit (Bio-Rad,
CA, USA).
Clonogenic assay
A549 or GM18366 cells were seeded at 500 cells/60-mm
dish and grown overnight. One hour prior to UV expo-
sure, cells were pre-incubated with SchB (0, 1, 10 and
30mM). After the removal of growth medium, cells were
sham treated or exposed to UV irradiation (20–75J/m
2).
The cells were cultured in a fresh growth medium supple-
mented with SchB. After incubating for 14 days, cells were
stained with 2% (w/v) methylene blue (dissolved in 50%
ethanol). Colonies were counted and the value was nor-
malized to that of the sham-treated group with or without
SchB treatment.
Immunoblot analysis
For immunoblot analysis, 50mg of proteins was loaded
and separated by SDS–PAGE, and the protein bands
were transferred to a nitrocellulose membrane by electron
blotting. The membrane was blocked by 5% skim milk in
Tris-buﬀered saline containing 0.1% Triton X-100 for 1h
at room temperature. Immunoblotting was performed
using primary antibodies for p53 (Calbiochem,
Darmstadt, Germany), phospho-p53 (Cell Signaling
Technologies, NJ, USA), phospho-ATM (Rockland
Immunochemicals, PA, USA), phospho-Chk1 (Cell
Signaling Technologies), ATR (Bethyl Laboratories, TX,
USA), tubulin (Sigma) and GAPDH (Santa Cruz, CA,
USA), and these antibodies were incubated with the mem-
brane for 16h at 48C. Secondary antibodies conjugated
with horse radish peroxidase (Zymed laboratories, CA,
USA) were incubated for 1h at room temperature.
Target proteins were visualized using an ECL reaction
kit (Amersham, NJ, USA) and a chemiluminescence ﬁlm
(Amersham).
siRNA experiments
siRNA oligonucleotides were synthesized by Qiagen.
The target sequences of the siRNA duplex for ATM and
ATR were 50-AAG CGC CTG ATT CGA GAT CCT-30
and 50-AAG ACG GTG TGC TCA TGC GGC-3’,
respectively. A siRNA for GFP with a target sequence
of 50-CGGCAAGCTGACCCTGAAGTTCAT-30 was
used for the negative control. The siRNA duplexes were
transfected into A549 adenocarcinoma cells using the
oligofectamine method (Invitrogen) and Opti-MEM
(Invitrogen), according to the manufacturer’s protocol.
The siRNA-transfected cells were incubated with growth
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Cell cycle analysis
To visualize the cell cycle transition from the G2/M phase
to the G1 phase, ﬂow cytometric analysis was performed.
A549 cells were cultured with 0.1mg/ml nocodazole for
16h in order to synchronize the cells into the G2/M
phase. After nocodazole treatment, 85% of the cells
were in the G2/M phase. SchB or caﬀeine was added to
medium 1h prior to the termination of nocodazole incu-
bation. Cell populations in various phases of the cell cycle
were analyzed using ModFit LT2.0 software.
G2/M checkpoint analysis
Phosphorylation of histone H3 at Ser10 was used for mon-
itoring mitosis. Asynchronous and synchronous cells were
both ﬁxed with ice-cold 70% ethanol and permeabilized
with 0.25% Triton X-100 in PBS on ice for 30min. The
cells were then incubated with 1mg of polyclonal rabbit
phospho-histone H3 (Ser10) antibody (Upstate, NY,
USA) and FITC-conjugated goat anti-rabbit IgG anti-
body (Sigma) for 4h and 1h at room temperature, respec-
tively. Counter-staining with 10mM propidium iodide was
performed by subsequent incubation for 20min at room
temperature. Cells were analyzed by FACS using a ﬂow
cytometer (Beckman-Coulter, CA, USA).
S-phase analysis
The intake of 5-bromo-20-deoxyuridine (BrdU) during
DNA synthesis was estimated to account for the S-phase
checkpoint of cells (21). In brief, 10mM BrdU in medium
was incubated for 1h after UV irradiation. Cells were col-
lected and ﬁxed in 70% ice-cold ethanol, and kept for 2h
at  208C. Cells were washed and incubated in 2N HCl for
30min at room temperature to denature the DNA. The
acid solution was then neutralized with 0.1M Na2B4O7
(pH 8.5) and subsequently washed with PBS. The cells
were incubated with 1mg of polyclonal rabbit BrdU anti-
body (Sigma) and FITC-conjugated goat anti-rabbit IgG
antibody (Sigma) for 4h and 1h at room temperature,
respectively. Counter-staining with 10mM propidium
iodide was performed by subsequent incubation for
20min at room temperature. Cells were analyzed by
FACS using a ﬂow cytometer (Beckman-Coulter).
Effect of SchB on the association of ATR with ATRIP
Flag-tagged ATR was expressed in HEK293T cells follow-
ing transient transfection with a ﬂag-tagged ATR vector
(generous gift from Dr R.T. Abraham), and the expressed
proteins were immuno-precipitated for 4h at 48C with
20mg of anti-Flag
R M2 monoclonal antibody (Sigma)
from 2mg of cell lysates. Subsequently, the proteins
were subjected to immunoblot analysis as shown above
using an anti-ATRIP antibody (Cell Signaling
Technologies).
Kinase assay
Flag-tagged ATR was expressed in HEK293T cells using
the same method as described above from 5mg of cell
lysates. ATM was puriﬁed by immunoprecipitation from
A549 cell lysates, using anti-ATM monoclonal antibody
(Rockland Immunochemicals). Cell lysates with antibo-
dies were subsequently incubated with Protein-G
Sepharose (Amersham) for 1h at 48C independently.
Immunocomplexes were washed twice with TGN buﬀer
(50mM Tris, pH 7.4, 50mM glycerophosphate, 150mM
NaCl, 1% Tween20, 10% glycerol), and once with kinase
buﬀer, containing 10mM HEPES (pH 7.5), 50mM glycer-
ophosphate, 50mM NaCl, 10mM MgCl2 and 10mM
MnCl2. The phosphorylation reaction was performed by
mixing 1mg of recombinant PHAS-I (Alexis Biochemicals,
CA, USA), a substrate for ATR kinase, with 10mM
32P ATP (50Ci/mmol; Amersham), as previously
described (22). After incubation for 20min at 308C, the
reaction was terminated by adding 4 volumes of SDS
sample loading buﬀer, and samples were then subjected
to 12% SDS–PAGE. Gels were dried and analyzed by
autoradiography. A linear relationship between ATR
activity and the level of PHAS-I phosphorylation was ver-
iﬁed under the above assay conditions. Chk1 (Upstate),
PI3K (Echelon Biosciences Inc, UT, USA), DNA-PK
(Promega) and mTOR (Calbiochem) activities were
measured using respective assay kits according to the man-
ufacturer’s instructions.
Effect of SchB on MAPK activity
To examine the speciﬁcity of SchB toward diﬀerent signal-
ing pathways, SchB was tested for its eﬀect on the MAPK
kinase signaling pathway. Cells were ﬁrst incubated with
PD098059, an inhibitor of MEKs, for 15min, or SchB for
60min after serum starvation for 16h (22). Then, cells
were treated with 100ng/ml PMA for 5min, and then
harvested for immunoblot analysis of extracellular-
regulated kinase (ERK) phosphorylation, using the anti-
bodies for phosphorylated ERK (Thr202/Tyr204) and
total ERK (Cell Signaling Technologies).
Statistical analysis
Statistical analysis was performed using the statistical
package for social science (SPSS) software. The half-max-
imal inhibitions (IC50) of ATR kinase by SchB were cal-
culated by solving the respective linear models. P<0.05
was considered statistically signiﬁcant.
RESULTS
Effect of SchB treatment on cell viability after UV
irradiation
We investigated whether SchB (Figure 1) treatment aﬀects
cell survival following DNA damage induced by UV and
g-irradiation (IR). The viability of A549 cells was moni-
tored by clonogenic assay for 14 days after UV or IR
exposure in the presence or absence of SchB. SchB
showed no eﬀect on cell viability (Figure 2A). Although
SchB-untreated cells showed a moderate decrease in
5680 Nucleic Acids Research, 2009, Vol. 37,No. 17viability following UV irradiation, a signiﬁcant decline in
viability was observed in SchB-treated cells. Notably, the
concentrations of SchB treatments at 30mM or higher
were lethal in less than 3 days after UV-induced DNA
damage (Figure 2B), and similar eﬀects were observed in
UV-irradiated HEK293T and HeLa cells (data not
shown). The critical eﬀect of caﬀeine was not observed
at the same concentrations as SchB in the UV-irradiated
cells (data not shown). These results suggest that SchB
may inﬂuence the cellular DNA damage response induced
by UV irradiation regardless of the cell type. Moreover,
such a marked decline in viability was not seen in cells
treated with gIR (Figure 2C). Apparently, DNA damage
checkpoint mechanism(s) may be involved in the UV-
sensitizing action of SchB in cancer cells.
Sch B treatment abolishes the UV-activated G2/M and
S-phase checkpoints
To examine the eﬀect of SchB on the abrogation of DNA
damage checkpoints, we measured the cell cycle transition
from the G2/M phase to the G1 phase using ﬂow cyto-
metric analysis (Figure 3A). Cells enriched in the G2/M
phase were observed in A549 cells treated with nocodazole
for 16h before UV exposure (indicated by the gray histo-
gram), and an increase in the population of cells in the G1
phase was observed 1h after removing nocodazole
(Figure 3A; left upper and lower panels). UV exposure
inhibited the cell cycle transition from the G2/M phase
to the G1 phase in a dose-dependent manner (upper
panels of Figure 3A and B). In turn, SchB treatment 1h
prior to and after the removal of nocodazole signiﬁcantly
increased the population of G1 cells. Caﬀeine also
increased the percentage of G1 cells, but the increase
was not signiﬁcant compared with the control. To conﬁrm
the observations, we examined the eﬀect of SchB on mito-
sis in UV-irradiated cells using phospho-antibody (Ser 10)
against Histone H3 (Figure 3C). The percentage of
P-Histone H3-positive cells (indicative of cell population
in the G2/M phase) 1h after removing nocodazole was
about 17%. The proportion of mitotic cells decreased in
a UV intensity-dependent manner in cells without SchB
treatment. As expected, SchB treatment induced signiﬁ-
cant accumulation of mitotic cells more than caﬀeine
treatment and the control. We further tested a lower
UV condition which is to minimize the inﬂuence of DSB
response. SchB treatment completely abolished the G2/M
checkpoint even in lower UV irradiation as 10J/m
2 in
asynchronous cells (Figure 3D). These results clearly
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Figure 2. SchB treatment causes a decrease in cell viability after UV
irradiation. Relative cell viability was measured by clonogenic assay.
A549 cells were seeded as 500 cells/60-mm dish, and then incubated
for 24h before the experiment. The cells were subjected to 1h pre-
incubation and 14 days post-incubation (A) with SchB (0, 1, 10 and
30mM) after (B) UV irradiation (0, 20 and 50J/m
2)o r( C) IR irradia-
tion (0, 2 and 6Gy). Values are expressed as mean SD (n=3).
 P<0.05 versus SchB untreated control.
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Figure 1. Chemical structure of SchB.
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5682 Nucleic Acids Research, 2009, Vol. 37,No. 17indicate that SchB abrogated the G2/M checkpoint during
UV-induced DNA damage. The intracellular uptake of
BrdU during 2h incubation was measured to estimate the
eﬀect of SchB on S-phase checkpoint abrogation
(Figure 3E). The cell population in the S phase was about
42% in asynchronous cells, and UV treatment decreased
this to 20% in a dose-dependent manner (Figure 3F). The
treatment of SchB for 1 or 2h before and after UV irradi-
ation did not markedly decrease the cell population in the
S phase. This result indicates that SchB inhibited not only
the G2/M phase but also the S-phase checkpoints in DNA
damage response induced by UV.
SchB inhibits the phosphorylation of checkpoint proteins
in vivo
To examine whether SchB directly aﬀects DNA damage
response especially in ATM- or ATR-related signal
transduction pathways in cells, we monitored the phos-
phorylation of p53 at Serine15 (Ser15), a direct target of
ATM/ATR during DNA damage response induced by IR
or UV irradiation (1,2,23–25), using phosphorylation site-
speciﬁc antibodies. Indeed, the level of p53 phosphoryla-
tion at Ser15 was increased by exposure to IR (10Gy) or
UV (20J/m
2) in A549 cells in the absence of SchB treat-
ment (Figure 4A, top panel, lanes 1, 3, 5). Interestingly,
SchB treatment at 30mM decreased the level of p53 phos-
phorylation at Ser15 following UV but not IR exposure
(lanes 3–6), suggesting that SchB inhibited ATR- but not
ATM-dependent phosphorylation of p53 at Ser15.
Consistent with the inability of SchB to inhibit ATM-
dependent Ser15 phosphorylation, SchB did not alter the
auto-phosphorylation of ATM at Ser1981, which is asso-
ciated with ATM activation following DNA DSBs
(Figure 4A, third panel from top, lanes 3-6). In order to
gain a mechanistic insight into the inhibitory eﬀect of
P-ATM (Ser1981)
p53
P-p53 (Ser15)
IR Control
SchB
UV
123456
Tubulin
A
p53
P-p53 (Ser15)
Tubulin
UV
Control 100 30 10
SchB ( M)
1 2 3 4 5 6
B
P-Chk1 (Ser317)
Chk1
1 2 3 4 5 6
P-p53 (Ser15)
Tubulin
SchB
Caffeine
UV
C
P-Chk1 (Ser317)
Chk1
p53
NT
ATR
ATRIP
IgG
UV
SchB
D
1 2 3 4
–
–
–
–+
–
–++ ––
+
+
+
– +
– –
–
– + + – + –
– ++ + +
+ – +
Figure 4. Inhibitory eﬀects of SchB treatment on checkpoint proteins. (A) A549 cells were pre-incubated with or without 30mM SchB for 1h prior to
induction of DNA damage. After pre-incubation, cells were subjected to 10Gy of IR or 20J/m
2 of UV irradiation, and cultured at 378C for 1h and
3h, respectively. (B) Dose-dependent eﬀects of SchB on the phosphorylation level of p53 and Chk1 were observed by adding increasing concentra-
tions of SchB before and after induction of DNA damage by UV irradiation (20J/m
2). A549 cells were incubated with a proteasome inhibitor (50mM
LLnL) throughout the experiments in A, B and C to avoid proteasome-dependent protein degradation. Equal loading of extracted proteins was
conﬁrmed by determining immuno-stained tubulin. (C) A549 cells were pre-incubated with or without 30mM SchB or 10mM caﬀeine for 1h prior to
induction of DNA damage. After pre-incubation, cells were subjected to UV irradiation (20J/m
2), and cultured at 378C for 3h. (D) Flag-tagged ATR
was expressed in HEK293T cells following transient transfection with a ﬂag-tagged ATR, and the expressed proteins were immunoprecipitated. The
association of ATR with ATRIP was analyzed by immunoblot analysis.
Nucleic Acids Research, 2009,Vol.37, No. 17 5683SchB on ATR, we next investigated whether inhibition is
limited to the phosphorylation of Ser15 of p53. We found
that SchB also dose-dependently inhibited the phosphor-
ylation of another ATR substrate, Ser317 of Chk1 (26)
(Figure 4B, top and 3rd panel). Since a proteasome inhib-
itor LLnL was present in our UV irradiation experiments
(Figure 4A and B), the UV irradiation induced degrada-
tion of p53 protein was suppressed (Figure 4B, second
panel from top). To investigate the signiﬁcance of the inhi-
bition of ATR protein kinase activity by SchB, the phos-
phorylation of p53 and Chk1 was examined in SchB- and
caﬀeine-treated cells after UV irradiation (Figure 4C).
SchB markedly inhibited the phosphorylation of p53
(top panel, lanes 5 and 6) and Chk1 (3rd panel, lanes 5
and 6) in vivo, as was the case for caﬀeine. To exclude
the possibility of a decrease in phosphorylation of p53
and Chk1 through cell cycle synchronization induced
by SchB, the cell cycle distribution was analyzed with or
without SchB treatment. We found that SchB treatment at
30mM did not aﬀect cell cycle distribution, even after 6h
of incubation or 24h of incubation (data not shown).
Therefore, the decreased levels of p53 and Chk1 phos-
phorylation were not due to the diﬀerential distribution
of cells in various phases of the cell cycle. We further
examined whether or not SchB prevents the binding of
ATR to ATRIP, a critical interacting protein for ATR
activation during DNA damage response (Figure 4D).
After UV irradiation, over-expressed ATR-wt in
HEK293 cells was strongly associated with ATRIP (2nd
panel, lane 3); however, SchB did not reduce the binding
amounts of ATRIP to ATR in vivo (2nd panel, lane 4).
These results suggest that the suppression of UV-induced
phosphorylation of p53 at Ser15 and Chk1 at Ser317 by
SchB treatment may be a direct inhibition of ATR by
SchB, and is not due to the association with ATRIP.
SchB inhibits ATR kinase activity in vitro
To directly address the question of whether SchB inhibits
ATR protein kinase activity, Flag-tagged ATR was
expressed in HEK293T cells by transient transfection,
and then isolated for in vitro kinase activity assay. After
puriﬁcation of Flag-tagged protein kinase by immunopre-
cipitation with Flag-M2 antibody, we measured in vitro
ATR kinase activity toward PHAS-I, a speciﬁc substrate
of these kinases. ATM kinase activity was measured with
endogenous ATM puriﬁed by anti-ATM antibody. To
verify the speciﬁcity of SchB toward ATR, activities of
Chk1, phosphoinositide 3-kinase (PI3K), DNA-dependent
protein kinase (DNA-PK) and the mammalian target of
rapamycin (mTOR) were also measured. The activity of
ATR was markedly inhibited by increasing concentrations
of SchB, with an IC50 of 7.25mM (Figure 5A). In contrast,
the activity of immunopuriﬁed ATM protein kinase was
not aﬀected by SchB treatment at concentrations in the
micromolar range, with an IC50 of 1.74mM (Figure 5B).
Moreover, the activities of Chk1, PI3K, DNA-PK
and mTOR were not aﬀected by SchB treatment
(Figure 5C–F). These results indicate that SchB preferen-
tially inhibited the protein kinase activity of ATR rather
than ATM, Chk1 and other phosphoinositide 3-kinase
(PI3K) family members in vitro, regardless of their similar
roles to PI3K at DNA damage checkpoints.
SchB prevents ATR-dependent signaling pathway
If ATR is a direct target of SchB in vivo, the inhibitory
action of SchB should not be limited to the phosphoryla-
tion of p53 and Chk1. To address this point, we studied
whether SchB could also aﬀect the phosphorylation
of other ATR substrates. AT2KY cells, which are ATM-
deﬁcient ﬁbroblasts, were used to exclude the possibility of
a redundant function of ATM, which might phosphory-
late ATR substrates when ATR was inhibited by SchB.
Following UV irradiation, we monitored phosphoryla-
tions of p53 (Ser15), Chk1 (Ser317), SMC1 (Ser966) and
BRCA1 (Ser1423) using a series of phosphorylation site-
speciﬁc antibodies in western blot analysis. We found that
the phosphorylation of all tested ATR substrates were
inhibited by SchB treatment in the ATM-deﬁcient cells,
supporting the direct inhibition of ATR activity by SchB
(Figure 6A, lanes 3 and 4). To further conﬁrm these
results, we next used siRNA to deplete ATM in A549
cells (Figure 6B). SchB treatment was found to inhibit
UV-induced phosphorylation of p53 (Ser15) and Chk1
(Ser317) in both control siGFP- and siATM-treated cells
(Figure 6B top and 3rd panel; lanes 3, 4, 7 and 8). To
ensure the inhibitory potential of SchB in ATR-dependent
DNA damage checkpoint signaling, we performed the cell
viability test with ATR-deﬁcient Seckel syndrome ﬁbro-
blasts. Since this cell line remains proﬁcient in other
ATR-independent DNA damage responses (27), the
survival curve in UV exposed control culture was similar
(Figure 6C) to that of other cell lines such as A549
(Figure 2B). As expected, SchB did not show any eﬀect
on cell viability following UV irradiation, (Figure 6C).
The results indicate that SchB inhibited the signal trans-
duction from ATR to phosphorylation of all tested
ATR substrates in vivo, which is in agreement with the
inhibition of aﬃnity-puriﬁed ATR in vitro (Figure 5).
SchB does not affect mitogen-activated protein
kinase pathway in vivo
ATR is a member of the phosphoinositide 3-kinase-like
kinase (PIKK) family and contains a kinase domain
with motifs that are typical of the lipid kinase, PI3K.
To further investigate the speciﬁcity of SchB as an ATR
kinase inhibitor, we examined whether SchB aﬀects the
mitogen-activated protein (MAP) kinase pathway, which
is unrelated to the DNA damage response. Treatment of
A549 cells with phorbol 12-myristate 13-acetate (PMA)
after 16h serum starvation dramatically induced the
phosphorylation of ERK in A549 cells, as monitored by
p44 and p42 ERK phosphorylation using Western blot
analysis (Figure 7). While PD98059, a speciﬁc inhibitor
for MEKs (MAPK/ERK kinases), inhibited the phos-
phorylation of ERKs (Figure 7, top panel, lanes 2 and
6), SchB treatment, at a concentration that readily inhib-
ited ATR-dependent phosphorylation, did not change the
extent of the phosphorylation of ERKs (Figure 7, lane 4).
This result indicates that SchB is not a non-speciﬁc inhib-
itor of protein kinases in A549 cells.
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In order to avoid the carry-over of damaged DNA
to the next generation of cells, checkpoint signals pro-
vide a safeguard in several critical phases of the cell
cycle (1,2). The requirement of ATM and ATR for
checkpoint activation and cell survival following UV
exposure, IR irradiation or treatment with genotoxic
agents is well documented (7–9). ATM and ATR
phosphorylate various substrates including Chk1, p53,
NBS1, BRCA1 and SMC1. The disruption of DNA
damage checkpoints can lead to the chemo- and radio-
sensitization of cancer cells (3,28), thus inhibitors for
checkpoint kinases, particularly the ATM/ATR kinases
in proximity to the checkpoints, may prove to be beneﬁcial
in serving as radio/chemo-sensitizing agents for cancer
therapy (3,14)
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Figure 5. SchB treatment inhibits ATR kinase activity. Kinase activities of ATR (A), ATM (B), Chk1 (C), PI3K (D), DNA-PK (E) and mTOR (F)
were measured in vitro as phosphorylation activity in the presence of SchB. A ﬂag-tagged ATR-wt plasmid was transfected into HEK293T cells. ATR
protein kinases were puriﬁed by immunoprecipitation using anti-Flag M2 antibody and Protein-G agarose. The endogeneous ATM protein was
puriﬁed from A549 cell lysates with anti-ATM antibody. Kinase activity was monitored for 20min at 308C. Chk1 (Upstate), PI3K (Echelon
Biosciences), DNA-PK (Promega) and mTOR (Calbiochem) activities were measured using respective assay kits according to the manufacturer’s
instructions. Values are presented as mean SD (n=3).
Nucleic Acids Research, 2009,Vol.37, No. 17 5685In the present study, we have shown that SchB, an
active ingredient of F. schisandrae, represents a novel
and potent ATR protein kinase inhibitor. SchB has long
been used for the treatment of hepatitis and heart failure
in China (16). Interestingly, Li et al. (18) have recently
reported that SchB signiﬁcantly enhanced DOX-induced
apoptosis in human hepatic carcinoma and breast cancer
cells. As DOX can activate both cellular ATR and ATM
kinase activities in cultured cells (29,30), our ﬁnding of the
inhibition of ATR kinase in vivo and in vitro by SchB
suggests that SchB may enhance DOX-induced cancer
cell death by inhibiting the ATR-dependent checkpoint
signals. The ﬁnding of a dose-dependent decrease in cell
survival as induced by SchB following UV irradiation
(Figure 2) suggests that SchB inﬂuence the DNA
damage response following UV irradiation. A modest dif-
ference in cell survival was observed between untreated
and SchB-treated cells after IR irradiation. In relation to
this, it is known that ATR and ATM are activated by
diﬀerent types of DNA damage (1,2). Single-strand
break (SSB) generated by UV irradiation or DNA-dama-
ging agents primarily activates ATR, whereas DSB pro-
duced by IR irradiation activates ATM (1,28). Consistent
with the reduction in cell survival by SchB following UV
irradiation, SchB treatment disrupted the G2/M check-
point activated by UV exposure, but had a weak eﬀect
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Figure 6. SchB prevents ATR-dependent signaling pathway after DNA damage. (A) AT2KY ﬁbroblasts were pre-incubated with or without 30mM
SchB for 1h, and then subjected to UV irradiation (20J/m
2). The cells were harvested 4h later and phosphorylation levels of p53, Chk1, SMC1 and
BRCA1 were measured to assess checkpoint function. (B) A549 cells were transfected with siRNA for control (siGFP), ATM or ATR using the
oligofectamine method, and the cell extracts were immunoblotted with anti-phosphorylated p53, phosphorylated Chk1, total-ATM, total-ATR or
anti-tubulin. After 72h incubation for the knockdown of ATM or ATR, cells were subjected to UV irradiation (20J/m
2) followed by 4h incubation
with or without SchB (30mM) pre/post-incubation. The equal loading of an extracted protein was conﬁrmed using anti-monoclonal tubulin antibody.
(C) The cell viability was measured in ATR-deﬁcient Seckel syndrome ﬁbroblasts with or without SchB (0, 1, 10 and 30mM) after UV irradiation (0,
25, 50 and 75J/m
2). Values are expressed as mean SD (n=3).
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Figure 7. Phosphorylation of ERK at Thr202 and Tyr204. A549 cells
were pre-treated with 50mM PD098059 or 30mM SchB after serum
starvation for 16h. The phosphorylation of ERK was activated by
adding 100ng/ml PMA followed by a 5min incubation. The cells
were lysed and applied to immunoblot analysis. Equal loading of an
extracted protein was conﬁrmed using anti-monoclonal tubulin
antibody.
5686 Nucleic Acids Research, 2009, Vol. 37,No. 17on caﬀeine-treated cells (Figure 3B and C). The result
suggests that SchB might have an inhibitory eﬀect on
the ATR- rather than ATM-dependent checkpoint. In
good agreement with the ATR inhibition by SchB, the
G2/M checkpoint-disrupting eﬀect of SchB was more evi-
dent with a lower dose of UV, where the percentage of
mitotic cells was almost the same as the control cells
(Figure 3D). Bakkenist and Kastan (31) reported that
ATM activation occurred within minutes after IR irradi-
ation or hours after UV irradiation. Because phospho-
Histone H3-positive cells (i.e. mitotic cells) were measured
1h after UV irradiation to avoid an inﬂow of cells
from the S phase to the M phase in our G2/M checkpoint
study (Figure 3C), the eﬀect of SchB on mitosis at a higher
UV dose (50J/m
2) might be due to the participation of
ATM triggered by a higher UV dose, although the ratio
of contribution is still not yet clear. Nevertheless, a signif-
icant diﬀerence in mitotic cell populations between the
control and SchB-treated cells was still observed. Taken
together, the results unequivocally support the ATR
kinase-speciﬁc inhibitory eﬀect of SchB in DNA damage
response.
To understand the molecular mechanism(s) involved in
the above observed eﬀects of SchB, we examined how
SchB inﬂuences cellular DNA damage responses in
detail. We found that the levels of several cellular phos-
phorylated molecules after UV irradiation were decreased
by SchB treatment (Figure 4). Since both ATM and ATR
play a critical role in triggering the cascade of DNA
damage response (1,2), our result indicates that SchB
treatment can lead to the abrogation of DNA damage
response induced by UV irradiation via ATM and/or
ATR inhibition. It has been reported that p53 is phos-
phorylated at multiple sites in vivo by several diﬀerent
protein kinases (1,2,32). Since the speciﬁc and direct phos-
phorylation of p53 by ATR and ATM occurs at Ser15 in
response to UV, IR irradiation, or methylating agents
(32), Ser-15 phosphorylation serves as a useful biochem-
ical monitor for ATM and ATR activities in vivo after
DNA damage. Although Ser15 of p53 was phosphory-
lated after both IR and UV irradiation (Figure 4A),
SchB reduced only the extent of UV-induced phosphory-
lation. Therefore, the UV wavelength of 254nm used in
the present study was found to mainly activate the cellular
ATR activity (1,25,33). Moreover, the inhibition of p53
phosphorylation by SchB did not require the presence of
cellular ATM (Figure 6), and SchB did not aﬀect the acti-
vation of ATM kinase, as revealed by auto-phosphoryla-
tion of Ser1981 (Figure 4A). These observations strongly
suggest that SchB speciﬁcally inhibits ATR-dependent
phosphorylation of p53 at Ser15. On the other hand,
our data show that the phosphorylation of Chk1 at
Ser317, a speciﬁc and direct phosphorylation site of both
ATM and ATR, was also suppressed by SchB treatment in
a dose-dependent manner (Figure 4B). At the same time,
the S-phase checkpoint estimated by DNA synthesis in
cells was abrogated by SchB treatment (Figure 3E
and F). Therefore, the inhibitory eﬀect of SchB on DNA
damage checkpoints is not limited to one particular
ATR substrate that functions at the G2/M checkpoint.
How does SchB aﬀect ATR-dependent phosphorylation?
The result obtained from the in vitro phosphorylation
study suggests that ATR, but not ATM, is a direct
target for the inhibitory action of SchB (Figure 5),
which is in agreement with the observed inhibition of
the phosphorylation of all tested ATR substrates. On
the other hand, the association between ATR and
ATRIP, a typical mechanism of ATR activation after
the DNA damage in vivo (34,35), was not prevented by
SchB treatment (Figure 4D). Pertaining to this, we demon-
strated the inhibition of ATR activity by SchB in vivo,
comparable to the eﬀect of caﬀeine, a well-known inhibi-
tor of PI3K kinases, including ATR (Figure 4C). With
reference to IC50 values on ATR and ATM, SchB was
more potent than caﬀeine (7.25mM versus 1.1mM) (22).
The inhibition of p53 and Chk1 phosphorylation by SchB
implies that SchB is also likely involved in the G1/S and
S-phase checkpoint regulation through the speciﬁc inhibi-
tion of ATR protein kinase activity.
To conﬁrm the ATR-speciﬁc inhibition by SchB,
we further studied the eﬀect of SchB using AT2KY cells,
which are AT patient-derived ﬁbroblasts lacking func-
tional ATM, and siRNAs for ATM and ATR in A549
cells. The results indicate that the inhibitory eﬀect of
SchB on the phosphorylation of various ATM/ATR sub-
strates required the presence of ATR but not ATM
(Figure 6). Importantly, the inhibitory eﬀect of SchB on
the phosphorylation of ATR substrates was observed
in both BRCA1 and Chk1. This observation, therefore,
further supports the speciﬁc action of SchB on ATR,
and the G2/M and S-phase checkpoint abrogation by
SchB shown in Figure 3 might also be due to the inhibition
of the ATR-BRCA1/Chk1/SMC1 pathway. Moreover,
SchB did not aﬀect the phosphorylation of ERKs, a
signal event mediated by MAP kinase but unrelated to
the DNA damage response. Furthermore, it is interesting
to note that the G2/M checkpoint-disrupting eﬀect of
SchB was not detectable in other dibenzocyclooctadiene
derivatives of F. schisandrae such as schisandrin C and
angeroylgomisin-A (generous gifts from Tsumura Co.,
Japan) (data not shown). This ﬁnding suggests a highly
speciﬁc action of SchB in the inhibition of the G2/M
checkpoint.
SchB may be used as a sensitizer in cancer therapy
because of its high speciﬁcity toward ATR. Conceivably,
SchB may be used for sensitizing malignant cells to anti-
cancer drugs such as DNA-damaging methylating/alkylat-
ing agents (36,37) and topoisomerase inhibitors (1,20) that
induce ATR activation. Finally, by abrogating the G2/M
checkpoint, SchB may be used as an adjuvant agent for
anti-cancer therapy, particularly for targeting cancer cells
that are resistant to chemo- and radiotherapy due to the
absence of functional p53 (38). Further in-depth study is
required to determine the clinical feasibility of SchB as a
sensitizing agent for anti-cancer therapy.
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